Prix Wegovy. Do you know how much Wegovy, this new weight loss drug, costs? Is it reimbursed by Social Security? Find out everything here, from the price in France to international prices.
Wegovy, based on semaglutide, is authorized in several countries to help with weight loss. But at what exact price? And will it be reimbursed in France? Here is the key information on this innovative treatment.
What is Wegovy?
Wegovy is an innovative drug for weight loss. It is created by Novo Nordisk and contains semaglutide . This component acts as an analogue of GLP-1. It stimulates insulin secretion and slows down gastric emptying.
This dual action helps regulate blood sugar and appetite. Thus, Wegovy facilitates weight loss.
Description and operation of Wegovy
Wegovy is a pre-filled injection pen for weekly subcutaneous injection. The dosage starts at 0.25 mg per week. It can go up to 2.4 mg per week.
The high dosage of Wegovy is greater than that of Ozempic . This allows you to lose weight dramatically.
Presentation of the medicine (weekly injection, dosages)
- Wegovy is available in different dosages: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg.
- Treatment begins at 0.25 mg per week. The dose increases by 0.25 mg every 4 weeks. The maintenance dose is 2.4 mg per week.
- Injections are given once a week. It is best to choose the same day for each injection.
“Wegovy enabled a significant percentage of patients (between 70% and 90%) to lose at least 5% of their weight, according to studies sponsored by Novo Nordisk.”
wegovy price
The price of Wegovy, a weight loss drug, is not fixed in France. But we expect to pay about 300 euros per month. This is similar to the price in Germany .
In America, the annual cost of Wegovy is about $13,600. That’s more than $1,130 per month.
The French Social Security has not yet decided whether it will cover the cost of Wegovy. The High Authority of Health thinks that Wegovy is useful. But it also says that other treatments already exist.
Reimbursement by Social Security could be partial. It could be limited to people with a high BMI and health problems.
Wegovy Price Comparison in Different Countries
- In Belgium, a box of Wegovy with 4 single-use needles costs €226.
- In Germany, the price of Wegovy is €301.91 for a four-week treatment at the maintenance dose.
- In Germany, the initial dose of Wegovy is marketed at €171.92 for a period of four weeks.
The price differences between countries show the importance of comparing Wegovy costs . It is also important to know the reimbursement options in your country for affordable treatment.
Wegovy and weight loss
Studies show that Wegovy* helps people lose weight a lot. Patients lose an average of 15-25% of their initial weight. This means that for a weight of 150 kg, you can lose between 22.5 and 37.5 kg.
It is crucial to understand that each person reacts differently. Results vary depending on many personal factors.
Weight Loss Goals with Wegovy*
- Average expected weight loss: 15 to 25% of initial weight
- For a 150 kg patient, this equates to a loss of 22.5 to 37.5 kg.
- However, results can vary considerably between individuals.
Wegovy* is not a miracle solution. You need to change your lifestyle habits for it to work well. Eating healthy and exercising regularly are essential. Medical monitoring is also crucial to keep the weight off.
“Wegovy* is an effective tool to help patients achieve their weight loss goals, but it must be accompanied by a lasting change in lifestyle habits.”
Side effects of Wegovy
The drug Wegovy (semaglutide) helps to lose weight. But you should know about the possible side effects . The most common effects mainly affect the digestive system:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach ache
There are also other side effects . For example, fatigue or hypoglycemia . These problems are more common at the beginning and when the dose increases. But they decrease over time .
“More than 2,600 patients received Wegovy for up to 68 weeks in four studies, and more than 1,500 patients received placebo. Patients receiving Wegovy lost an average of 12.4% of their baseline body weight compared with those receiving placebo.”
If the side effects are too strong, talk to your doctor. He or she may adjust the dose or find another solution. Every person is different, so a personalized approach is crucial to determine if Wegovy is right for you.
Doctors’ reviews about Wegovy
Experts say that Wegovy is safe and effective against obesity. But, it should be used when other methods have not helped. This includes changes in diet and exercise.
Wegovy’s place in therapeutic strategy
The High Authority of Health recommends Wegovy for certain patients. This includes those with a BMI ≥ 35 kg/m² and a weight-related disease. It is also recommended after having tried other methods without success.
Prescription conditions
Only obesity specialists can prescribe Wegovy for the first time. Treatment should go hand in hand with a reduced diet and regular exercise.
Doctors warn against the misuse of other weight loss drugs. This includes Ozempic without a proper prescription.
“For adult patients with an initial body mass index (BMI) ≥ 35 kg/m² and aged ≤ 65 years, the rate of weight loss at six months should be less than 5% for Wegovy to be considered for reimbursement.”
Wegovy reimbursement by Social Security
Wegovy is a promising drug to combat obesity. But its reimbursement by the French Social Security is uncertain. The High Authority of Health has given its opinion. It considers the medical service of Wegovy important, but no more than the alternatives.
Reimbursement for Wegovy could be partial. It could be limited to patients with high BMI and health problems. Private insurers will also have to say whether they will cover the cost of this treatment.
To benefit from Wegovy reimbursement in France, certain conditions must be met:
- A BMI equal to or greater than 30
- Unsuccessful attempts at weight loss without medication
- Medical supervision
- Participating in a weight loss diet program
- Increased physical activity
You will also need to apply for Social Security coverage . A medical prescription and compliance with medical recommendations are required.
Reimbursement of Wegovy in France is currently uncertain. The drug is not yet available. Each case will be assessed separately to determine whether it is eligible for coverage.
Comparison with other weight loss drugs
Wegovy, Saxenda and Ozempic are all weight loss treatments. But they have important differences. Let’s see their characteristics and results.
Wegovy vs Saxenda
Wegovy has more semaglutide than Saxenda. This helps to lose more weight.
Studies show that Wegovy helps to lose 35 pounds. Saxenda helps to lose 15 pounds at the maximum dose.
Wegovy vs Ozempic
Ozempic is an antidiabetic treatment that helps with weight loss. But it is not approved for weight loss in Canada. Wegovy is approved for this.
Wegovy has a higher dose than Ozempic. This helps reduce HbA1c by more than 3% with Wegovy, compared to 2.2% with Ozempic.
| Features | Wegovy | Saxenda | Ozempic |
|---|---|---|---|
| Active substance | Semaglutide | Liraglutide | Semaglutide |
| Maximum dose | 2.4 mg | 3 mg | 2.0 mg |
| Mean reduction in HbA1c | 3% | N / A | 2.2% |
| Average weight loss | 35 pounds | 15 pounds | 15 pounds |
| Weight loss indication | Yes | Yes | No (Canada) |
Despite their common therapeutic class, these drugs have differences. It is necessary to follow the prescription recommendations for each treatment comparison wegovy saxenda, comparison wegovy ozempic, differences slimming treatments .
Misuse of other weight loss medications
Experts warn against the misuse of certain drugs to lose weight. Treatments such as Ozempic or Phentermine and Topiramate are sometimes abused. This can be very dangerous for health.
These medications are not approved for weight loss. Using these medications without medical supervision is dangerous. They can cause serious side effects and significant risks.
You should not buy these weight loss drugs without a prescription . Only a doctor can prescribe the right treatment. He will do so after a complete examination and check-up.
| Medicine | Misuse for weight loss | Risks and dangers |
|---|---|---|
| Ozempic | Use in non-diabetic patients | Risk of serious side effects, significant weight loss that may be difficult to maintain |
| Phentermine | Non-medical use for weight loss | Addiction, heart problems, high blood pressure |
| Topiramate | Non-medical use for weight loss | Neurological risks, concentration problems, drowsiness |
Diversion of antidiabetic weight loss drugs is a global problem. It has increased significantly in 2023. Manufacturers are struggling to meet demand, causing shortages.
“Misuse of these drugs can lead to weight loss of up to 15%, but the health risks are far too great. It is essential to use these treatments only under strict medical supervision.”
Health authorities are closely monitoring the use of these drugs. They want to prevent risks to public health.
Shortage and availability of Wegovy in France
Wegovy, a weight loss drug, arrived in France in August 2022. However, its sale was delayed by a shortage of this type of drug.
Supply problems have also affected Wegovy. Novo Nordisk is struggling to meet demand. Experts say these problems should improve soon.
The availability of Wegovy in pharmacies may be limited at first. Novo Nordisk has invested 2.1 billion euros to increase production of Wegovy.
“By 2030, it is estimated that there will be nearly a billion obese people in the world, which creates a strong demand for this type of slimming treatment,” underlines one expert.
The prices of these drugs are still too high for many patients. Laboratories must find a good balance between availability and affordability.
Patient Testimonials and Reviews
The drug Wegovy is not yet available in France. However, wegovy patient reviews can be found online. These wegovy feedbacks show the results and impressions of patients.
Patients report losing a lot of weight with Wegovy. They have lost between 15 and 25% of their initial weight. Many have also seen their health improve and their obesity-related problems decrease.
“I lost 70 kilos after two obesity surgeries in the early 2000s. But the weight quickly came back. With Wegovy, I finally managed to stabilize my weight and feel better in my body.” – Anne-Sophie Joly, 52 years old
Gastrointestinal side effects such as nausea and diarrhea are common, especially early on. Some people have had to stop treatment because of these problems.
It is crucial to follow your doctor’s instructions regularly to get the most out of Wegovy.
| Name | Age | Initial weight | Final weight | Weight loss |
|---|---|---|---|---|
| Nicholas | 52 years old | 123 kg | 113 kg | 10 kg |
| Marianne | 69 years old | 123 kg | 113 kg | 10 kg |
| Albert | 54 years old | 123 kg | 113 kg | 10 kg |
| Cecile | 51 years old | Not communicated | Not communicated | 10 kg |
More than 7,000 people have tested Wegovy. Among them, 65.3% are women and their average age is 48.5 years. Most (82.3%) have a BMI between 40 and 50 kg/m².
Precautions for using Wegovy
To use Wegovy safely, one should follow the instructions for use. This includes regular medical monitoring and adding lifestyle changes.
Medical monitoring recommended
Using Wegovy requires close monitoring by an obesity professional. This monitoring includes several important steps:
- Before starting treatment, to check that the prescription criteria are met
- During treatment, in order to gradually adjust doses and monitor possible side effects
- When stopping treatment, to ensure that weight loss is maintained in the long term
Association with diet and physical activity
The use of Wegovy should be accompanied by sustainable changes in lifestyle. This includes:
- Adopting a balanced low-calorie diet
- Regular practice of suitable physical activity
These changes are crucial to improve the effectiveness of treatment. They help prevent weight regain. They help get the most out of Wegovy .
“Wegovy should be used with caution and under close medical supervision to ensure its long-term effectiveness and safety.”
Wegovy as a last resort for obesity
The High Authority of Health recommends that Wegovy should not be used except as a second-choice treatment. It is intended for adults with a BMI of 35 kg/m² or more and a weight-related comorbidity. This medication should be used as a last resort , after trying other weight loss methods.
The first step in managing obesity is to change your lifestyle. This includes eating better and getting more exercise. Medical and psychological support is also essential. Drug treatment, such as Wegovy, is an additional option for those who have not been able to lose weight by other means.
| Stephane’s case | Results |
|---|---|
| Age: 50 years old | Initial weight: 145 kg |
| Initial BMI: 41 | Weight loss: 25 kg in 8 months |
| Physical activity: 2,000 to 6,000 steps/day | Wegovy dose : 2.4 mg/week |
Wegovy is a last resort treatment option for severe obesity. It is recommended for those who have failed to lose weight by other means .
“Semaglutide, known under the trade names Ozempic and Wegovy, has revolutionized the treatment of obesity.”
Conclusion
Wegovy, a drug based on Semaglutide, is a new option for treating obesity. It is effective for weight loss, but it should not be the first option. It is intended for patients with a very high BMI and associated health problems.
Wegovy should be used under the supervision of a doctor. It should be taken with a reduced diet and exercise. Reimbursement by Social Security is not yet confirmed. It is also important not to use other weight loss medications without a prescription, as this can be very dangerous.
In short, Wegovy is an effective treatment for weight loss. But it should be used with caution and under medical supervision. It is crucial to follow the advice of doctors and avoid dangerous alternative solutions.
